BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Lumavita AG Announces New Funding


6/18/2009 11:18:40 AM

18 June 2009, Basle, Switzerland: Lumavita AG, the Swiss biopharmaceutical company specializing in novel anti-infectives for Women’s Health, announces today that it has raised CHF6m (€4m) in an extension to the Series A round the Company initiated in September 2008. The total raised in this financing round is CHF24m.

The new funds have been raised from new investor HealthCap and existing investor, Endeavour Vision. Both Magnus Persson of HealthCap and Olivier Valdenaire from Endeavour Vision will join Lumavita’s Board of Directors.

In March, Lumavita received preliminary marketing approval in Switzerland for its first product, FemiFect® (pentamycin), for the treatment of all three causes of vaginitis. The funds raised will be used to build Lumavita’s commercial partnering network for Femifect in anticipation of its submission and launch in more than 100 countries around the world beginning this year, and to finance two on-going development projects.

Dr Magnus Persson, partner at HealthCap, said, “Lumavita is uniquely positioned as a European biopharmaceutical company in that it is close to launching its first product, has a compelling pipeline focussed on Women’s Health and a world-class management team. HealthCap has followed the projects for some time and is delighted now to invest in Lumavita and to take an active part in its future success.”

Nicholas Benedict, CEO of Lumavita, said, “We have a very strong group of investors and will undoubtedly benefit from their input and support in growing our company. Our priorities are to gain FemiFect marketing approvals and launch the product in our target markets, alongside completing the development of both the high-dose formulation of FemiFect and of LMV-601, an anti-viral currently under evaluation for the treatment of cervical HPV.”

About Lumavita AG

Lumavita AG is a biopharmaceutical company focusing on novel anti-infectives for women’s health. Lumavita AG was founded in August 2008 and is engaged in globally targeted Development and Commercialisation activities for its proprietary product portfolio. In June 2009 Lumavita AG closed its Series A financing of CHF24m. The Series A investors were Atlas Venture, BB Biotech Ventures, BioMedInvest, Endeavour Vision and HealthCap. The Company’s product portfolio includes FemiFect® (pentamycin) a polyene macrolide with a unique spectrum of coverage for the treatment of vaginitis, and LMV-601, a first-in-class PC.

PLC inhibitor for the potential treatment of infection of the cervix caused by Human Papilloma Virus. A dose-optimized formulation of FemiFect® is in Ph IIb clinical development, and LMV-601 is in late-stage pre-clinical development. Lumavita AG is headquartered in Basle, Switzerland.

Please visit our website at www.lumavita.com

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES